Literature DB >> 34753138

Splenic Micronodular T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: The Corticosteroid Pretreatment Hypothesis.

Benzion Samueli1, Karen Nalbandyan2, Daniel Benharroch2, Itai Levi3.   

Abstract

Splenic micronodular T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is derived from diffuse large B-cell lymphoma N.O.S., perhaps with some affinity with nodal THRLBCL. Of note, in contrast with the latter, the only lymph nodes involved in association with the splenic micronodular pattern of the disease are the splenic hilar lymph nodes. The possibility that corticosteroids, when prescribed prior to splenectomy, cause histopathological and functional modulations, apoptosis, necrosis, tissue shrinkage, which may obscure the diagnostic morphological features of this variant lymphoma and cause an underdiagnosis of this condition. The indications for glucocorticoid therapy are either related to the lymphoma itself, or else to other comorbidities, like asthma and autoimmune disorders. We propose that patients with the splenic subset of the disease are likely to have been prescribed corticosteroids prior to histopathologic examination of the involved spleen, causing disparate morphologies. However, a reviewer might accidentally dismiss the corticosteroid pretreatment which is thus overlooked. Apoptosis, induced by corticosteroids, is hypothesized as the major mechanism initiating the histopathological and functional changes in the splenic micronodular variant of the lymphoma.
© 2021 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Apoptosis; Corticosteroids; Shrinkage; Splenic micronodular B-cell lymphoma

Mesh:

Substances:

Year:  2021        PMID: 34753138      PMCID: PMC9227669          DOI: 10.1159/000520791

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   3.068


  24 in total

1.  T-cell-rich B-cell lymphoma presenting in the spleen: a clinicopathologic analysis of 3 cases.

Authors:  Shiyong Li; Karen P Mann; Jeannine T Holden
Journal:  Int J Surg Pathol       Date:  2004-01       Impact factor: 1.271

2.  Splenic micronodular T-cell/histiocyte-rich large B-cell lymphoma: effect of prior corticosteroid therapy.

Authors:  Elena Kan; Itai Levy; Daniel Benharroch
Journal:  Virchows Arch       Date:  2009-09-09       Impact factor: 4.064

3.  T-cell/histiocyte-rich large B-cell lymphoma.

Authors:  Stefania Pittaluga; Elaine S Jaffe
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

4.  Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base.

Authors:  Thomas A Ollila; John L Reagan; Adam J Olszewski
Journal:  Leuk Lymphoma       Date:  2019-07-09

5.  T-cell-rich B-cell lymphoma of the spleen.

Authors:  H F Betman; J W Vardiman; J Lau
Journal:  Am J Surg Pathol       Date:  1994-03       Impact factor: 6.394

6.  Glucocorticoids induce apoptosis in human monocytes: potential role of IL-1 beta.

Authors:  M Schmidt; H G Pauels; N Lügering; A Lügering; W Domschke; T Kucharzik
Journal:  J Immunol       Date:  1999-09-15       Impact factor: 5.422

7.  T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity.

Authors:  R Achten; G Verhoef; L Vanuytsel; C De Wolf-Peeters
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

Review 8.  Glucocorticoids in T cell apoptosis and function.

Authors:  M J Herold; K G McPherson; H M Reichardt
Journal:  Cell Mol Life Sci       Date:  2006-01       Impact factor: 9.261

9.  Induction of apoptosis by dexamethasone in the B cell lineage.

Authors:  K Andréau; C Lemaire; V Souvannavong; A Adam
Journal:  Immunopharmacology       Date:  1998-07

10.  Rare Causes of Isolated and Progressive Splenic Lesions: Challenges in Differential Diagnosis, Evaluation, and Treatment of Primary Splenic Lymphomas.

Authors:  Ryan B Sinit; Russell K Dorer; John Paul Flores; David M Aboulafia
Journal:  Clin Med Insights Blood Disord       Date:  2020-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.